Ampliphi Biosciences Corp (APHB) 2.06 $APHB
AmpliPhi Biosciences to be Granted European Patent Covering the Use of Phage Therapy to Resensitize Bacterial Infections To Antibiotics
BusinessWire - Thu Jun 02, 7:45AM CDT
AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that the European Patent Office has issued a decision to grant AmpliPhi patent No. 2136826, for the "Beneficial effects of bacteriophage treatments". A corresponding patent has been granted in Australia and a species-specific patent for Pseudomonas aeruginosa has been granted in the United States. Additional patents are pending in Canada, Japan and the United States.
APHB: 2.06 (-0.14)
AmpliPhi Biosciences Announces Pricing of Registered Direct Public Offering of Common Stock and Warrants
BusinessWire - Tue May 31, 9:53PM CDT
AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced the pricing of a registered direct offering of 2,127,660 shares of common stock and warrants to purchase up to an aggregate of 1,063,830 shares of common stock. Each share of common stock is being sold together with a warrant to purchase one-half of a share of common stock of AmpliPhi at a combined purchase price of $2.35. The warrants will be immediately exercisable at a price of $2.25 per full share of common stock for a period of five years from closing, which is expected to occur on June 3, 2016.
APHB: 2.06 (-0.14)
AmpliPhi Biosciences' CEO to Discuss Novel Approaches to Fighting Drug-Resistant Pathogens in Panel at BIO International
BusinessWire - Tue May 31, 9:38AM CDT
AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that M. Scott Salka, AmpliPhi's Chief Executive Officer, will participate in a panel discussion at this year's BIO International Convention.
APHB: 2.06 (-0.14)
AmpliPhi Biosciences Announces Start of First Phage Therapy Trial in U.S. Under IND
BusinessWire - Tue May 24, 7:36AM CDT
AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced it has dosed the first patient in its Phase 1 clinical trial to evaluate the safety of AB-SA01, AmpliPhi's proprietary phage cocktail targeting Staphylococcus aureus (S. aureus) infections, administered topically to the intact skin of healthy adults. The trial is being conducted under a Collaborative Research and Development Agreement with the U.S. Army and at the Walter Reed Army Institute of Research Clinical Trials Center in Silver Spring, Maryland.
APHB: 2.06 (-0.14)
AmpliPhi Biosciences Reports First Quarter 2016 Financial Results and Provides Corporate Update
BusinessWire - Thu May 12, 3:15PM CDT
AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced its financial results for the first quarter ended March 31, 2016.
APHB: 2.06 (-0.14)
AmpliPhi Biosciences to Host Conference Call and Webcast Discussion of First Quarter 2016 Financial Results on May 13, 2016
BusinessWire - Tue May 10, 7:45AM CDT
AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it will report financial results for the quarter ended March 31, 2016 on Thursday, May 12. AmpliPhi management will host a conference call at 8:30 a.m. Eastern Time on May 13, 2016 to review financial results and provide a corporate update.
APHB: 2.06 (-0.14)
AmpliPhi Biosciences Provides Update on Phase I Trial: Phage Therapy Well Tolerated in First Cohort
BusinessWire - Wed Apr 20, 11:30AM CDT
AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today provided an update on the progress of its ongoing first-in-man Phase I clinical trial for chronic rhinosinusitis patients treated with AmpliPhi's proprietary phage cocktail AB-SA01.
APHB: 2.06 (-0.14)
AmpliPhi Biosciences Terminates Collaboration Agreement with Intrexon
BusinessWire - Thu Apr 14, 7:45AM CDT
AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it has provided written notice to Intrexon to cancel the Exclusive Channel Collaboration (ECC) with Intrexon.
APHB: 2.06 (-0.14)
AmpliPhi Biosciences Presents Data Showing Bacteriophage Product Candidate Kills Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients
BusinessWire - Tue Apr 12, 3:15PM CDT
AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, presented data at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) summarizing both the in vitro and in vivo activity of its proprietary, investigational phage mix AB-PA01.
APHB: 2.06 (-0.14)
AmpliPhi Biosciences Reports Full-Year 2015 Financial Results
BusinessWire - Wed Mar 30, 3:15PM CDT
AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced its financial results for the fiscal year ended December 31, 2015.
XON: 28.96 (-1.03), APHB: 2.06 (-0.14)
AmpliPhi Biosciences to Host Full-Year 2015 Financial Results Conference Call and Webcast on March 30, 2016
BusinessWire - Tue Mar 29, 7:45AM CDT
AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it will report financial results for the fiscal year ended December 31, 2015 on Wednesday, March 30, 2016. AmpliPhi management will host a conference call at 4:30 pm Eastern Time on March 30, 2016 to review financial results and provide a corporate update.
XON: 28.96 (-1.03), APHB: 2.06 (-0.14)
AmpliPhi Biosciences CEO to Present at 28th Annual ROTH Conference
BusinessWire - Tue Mar 08, 7:45AM CST
AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that M. Scott Salka, AmpliPhi's CEO, will present a corporate overview on Tuesday, March 15, 2016 at the 28th Annual ROTH Conference at the Ritz Carlton in Dana Point, California.
XON: 28.96 (-1.03), APHB: 2.06 (-0.14)
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2015 - 78 Companies & Drug Profiles
M2 - Tue Feb 09, 10:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/ctt3q8/methicillinresist) has announced the addition of the "Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infectionsand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Methicillin-Resistant Staphylococcus Aureus (MRSA) InfectionsOverview - Therapeutics Development - Pipeline Products for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Overview - Pipeline Products for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Comparative Analysis - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics under Development by Companies - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics under Investigation by Universities/Institutes - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Products under Development by Companies - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Products under Investigation by Universities/Institutes - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Companies Involved in Therapeutics Development Companies Mentioned - Absynth Biologics Limited - Adenium Biotech ApS - AIMM Therapeutics B.V. - Alchemia Limited - Allergan Plc - AlphaMab Co., Ltd - Alvogen Korea - AmpliPhi Biosciences Corporation - AnGes MG, Inc. - Aphios Corporation - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bharat Biotech International Limited - BioDiem Ltd - BioSource Pharm, Inc. - C3 Jian, Inc - Cellceutix Corporation - Cempra, Inc. - ContraFect Corporation - CrystalGenomics, Inc. - CSA Biotechnologies LLC - Debiopharm International S.A. - DesignMedix, Inc. - Destiny Pharma Limited - Dong-A Socio Group - Ensol Biosciences Inc. - Excelimmune, Inc. - Galapagos NV - GangaGen Inc. - Helix BioMedix, Inc. - Hsiri Therapeutics, LLC - Ildong Pharmaceutical Co., Ltd. - Immupharma Plc - ImmuVen, Inc. - iNtRON Biotechnology Inc. For more information visit http://www.researchandmarkets.com/research/ct...llinresist
AGN: 246.96 (-0.16), AZN: 29.73 (+0.06), CEMP: 18.73 (-1.11), APHB: 2.06 (-0.14), GLPG: 60.01 (+2.51)
AmpliPhi Biosciences Announces Award of Federal Research Grant from Australia to its Collaboration Partner, Westmead Institute
BusinessWire - Tue Feb 09, 7:45AM CST
AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, congratulates the Westmead Institute's Centre for Infectious Diseases and Microbiology for winning an AUD $860,000 grant from the Australian Government to isolate and develop phages that target two serious human pathogens, E. Coli and Klebsiella. AmpliPhi will participate in the project by providing its proprietary expertise in bacteriophage isolation, characterization and manufacturing scale-up.
XON: 28.96 (-1.03), APHB: 2.06 (-0.14)
Acinetobacter Infections Pipeline Review, H2 2015
M2 - Tue Feb 02, 5:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/923dq5/acinetobacter) has announced the addition of the "Acinetobacter Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acinetobacter Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acinetobacter Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Acinetobacter Infections Overview - Therapeutics Development - Pipeline Products for Acinetobacter Infections - Overview - Pipeline Products for Acinetobacter Infections - Comparative Analysis - Acinetobacter Infections - Therapeutics under Development by Companies - Acinetobacter Infections - Therapeutics under Investigation by Universities/Institutes - Acinetobacter Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acinetobacter Infections - Products under Development by Companies - Acinetobacter Infections - Products under Investigation by Universities/Institutes - Acinetobacter Infections - Companies Involved in Therapeutics Development - Achaogen Inc. - Adenium Biotech ApS - AmpliPhi Biosciences Corporation - Aridis Pharmaceuticals LLC - AstraZeneca Plc - AvidBiotics Corp. - Emergent BioSolutions Inc. - Evaxion Biotech - F. Hoffmann-La Roche Ltd. - FAB Pharma - FOB Synthesis, Inc. - LegoChem Biosciences, Inc - Melinta Therapeutics, Inc - Microbiotix, Inc. - MicuRx Pharmaceuticals, Inc. - Nosopharm SAS - Novan, Inc. - Omnia Molecular Ltd. - Pfizer Inc. - Phylogica Limited - Sarepta Therapeutics, Inc. - Sealife PHARMA GMBH - Shionogi & Co., Ltd. - Synthetic Biologics, Inc. - Techulon, Inc. - Tetraphase Pharmaceuticals Inc. - Trana Discovery, Inc. - Vaxdyn, S.L. For more information visit http://www.researchandmarkets.com/research/92...netobacter
TTPH: 4.38 (-0.17), SYN: 2.09 (-0.02), EBS: 43.71 (+0.07), SRPT: 15.57 (-0.14), PFE: 34.69 (-0.18), AZN: 29.73 (+0.06), AKAO: 3.93 (+0.32), APHB: 2.06 (-0.14)
Cystic Fibrosis - Pipeline Review, H2 2015
M2 - Wed Jan 27, 8:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/llcrjt/cystic_fibrosis) has announced the addition of the "Cystic Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cystic Fibrosis. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Actelion Ltd - Akari Therapeutics, Plc - Alaxia SAS - AlgiPharma AS - AmpliPhi Biosciences Corporation - Arcturus Therapeutics, Inc - Aridis Pharmaceuticals LLC - Bayer AG - Boehringer Ingelheim GmbH - Carolus Therapeutics, Inc. - Celtaxsys, Inc. - Chiesi Farmaceutici SpA - Cilian AG - Concert Pharmaceuticals, Inc. - Corbus pharmaceuticals, Inc. - Cyclacel Pharmaceuticals, Inc. - DiscoveryBiomed, Inc. - Errant Gene Therapeutics, LLC - Galapagos NV - GlaxoSmithKline Plc - Grifols, S.A. - Grupo Praxis Pharmaceutical SA - Horizon Pharma Plc - Insmed Incorporated - Invion Limited - JHL Biotech, Inc. - Kamada Ltd. - La Jolla Pharmaceutical Company - Lamellar Biomedical Ltd - Laurent Pharmaceuticals Inc. - (30 Others) For more information visit http://www.researchandmarkets.com/research/ll...c_fibrosis
INSM: 11.93 (-0.42), CYCC: 4.40 (-0.18), HZNP: 17.81 (-0.08), KMDA: 3.71 (-0.04), GSK: 42.89 (+0.48), AKTX: 14.00 (-0.19), APHB: 2.06 (-0.14), CNCE: 13.42 (+0.02), GLPG: 60.01 (+2.51)
Pseudomonas Aeruginosa Infections Therapeutics Pipeline Review, H2 2015
M2 - Fri Jan 22, 5:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/npjzdg/pseudomonas) has announced the addition of the "Pseudomonas Aeruginosa Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pseudomonas Aeruginosa Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pseudomonas Aeruginosa Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pseudomonas Aeruginosa Infections Overview - Therapeutics Development - Pipeline Products for Pseudomonas Aeruginosa Infections - Overview - Pipeline Products for Pseudomonas Aeruginosa Infections - Comparative Analysis - Pseudomonas Aeruginosa Infections - Therapeutics under Development by Companies - Pseudomonas Aeruginosa Infections - Therapeutics under Investigation by Universities/Institutes - Pseudomonas Aeruginosa Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pseudomonas Aeruginosa Infections - Products under Development by Companies - Pseudomonas Aeruginosa Infections - Products under Investigation by Universities/Institutes - Pseudomonas Aeruginosa Infections - Companies Involved in Therapeutics Development - Achaogen Inc. - Adenium Biotech ApS - Aeolus Pharmaceuticals, Inc. - AlgiPharma AS - AmpliPhi Biosciences Corporation - AnGes MG, Inc. - Arch Biopartners, Inc. - Aridis Pharmaceuticals LLC - Arno Therapeutics, Inc. - AstraZeneca Plc - Biolytics Pharma - CSA Biotechnologies LLC - Evaxion Biotech - F. Hoffmann-La Roche Ltd. - FOB Synthesis, Inc. - GlaxoSmithKline Plc - GlycoMimetics, Inc. - Hsiri Therapeutics, LLC - Insmed Incorporated - Lascco SA - LegoChem Biosciences, Inc - Lytix Biopharma AS - MedImmune, LLC - Nosopharm SAS - Novabiotics Limited - Novan, Inc. - Omnia Molecular Ltd. - Pfizer Inc. - Polyphor Ltd. - Sanofi - Sarepta Therapeutics, Inc. - Sealife PHARMA GMBH - Sequoia Sciences, Inc. - Shionogi & Co., Ltd. - Soligenix, Inc. For more information visit http://www.researchandmarkets.com/research/np...seudomonas
INSM: 11.93 (-0.42), PFE: 34.69 (-0.18), AKAO: 3.93 (+0.32), GLYC: 8.97 (+0.29), GSK: 42.89 (+0.48), APHB: 2.06 (-0.14), SRPT: 15.57 (-0.14), ACH: 7.64 (-0.02), AZN: 29.73 (+0.06)
AmpliPhi Biosciences doses CRS patient with AB-SA01 in Phase 1 clinical trial
M2 - Thu Jan 21, 3:51AM CST
Antibacterial company AmpliPhi Biosciences (NYSEMKT:APHB) revealed on Wednesday that it has started treatment of the first patient under its Phase 1 clinical trial of AB-SA01 in Staphylococcus aureus (S. aureus) infections with chronic rhinosinusitis (CRS) that fail to respond to standard antibiotic treatment.
APHB: 2.06 (-0.14)
AmpliPhi Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial of AB-SA01
BusinessWire - Wed Jan 20, 7:45AM CST
AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announces it has dosed the first patient in its Phase 1 clinical trial of AB-SA01 for the treatment of Staphylococcus aureus (S. aureus) infections in patients with chronic rhinosinusitis (CRS) that fail to respond to standard antibiotic treatment.
XON: 28.96 (-1.03), APHB: 2.06 (-0.14)
AmpliPhi Biosciences to be Granted European Patent Covering the Use of Phage Therapy to Resensitize Bacterial Infections To Antibiotics
BusinessWire - Thu Jun 02, 7:45AM CDT
AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that the European Patent Office has issued a decision to grant AmpliPhi patent No. 2136826, for the "Beneficial effects of bacteriophage treatments". A corresponding patent has been granted in Australia and a species-specific patent for Pseudomonas aeruginosa has been granted in the United States. Additional patents are pending in Canada, Japan and the United States.
APHB: 2.06 (-0.14)
AmpliPhi Biosciences Announces Pricing of Registered Direct Public Offering of Common Stock and Warrants
BusinessWire - Tue May 31, 9:53PM CDT
AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced the pricing of a registered direct offering of 2,127,660 shares of common stock and warrants to purchase up to an aggregate of 1,063,830 shares of common stock. Each share of common stock is being sold together with a warrant to purchase one-half of a share of common stock of AmpliPhi at a combined purchase price of $2.35. The warrants will be immediately exercisable at a price of $2.25 per full share of common stock for a period of five years from closing, which is expected to occur on June 3, 2016.
APHB: 2.06 (-0.14)
AmpliPhi Biosciences' CEO to Discuss Novel Approaches to Fighting Drug-Resistant Pathogens in Panel at BIO International
BusinessWire - Tue May 31, 9:38AM CDT
AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that M. Scott Salka, AmpliPhi's Chief Executive Officer, will participate in a panel discussion at this year's BIO International Convention.
APHB: 2.06 (-0.14)
AmpliPhi Biosciences Announces Start of First Phage Therapy Trial in U.S. Under IND
BusinessWire - Tue May 24, 7:36AM CDT
AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced it has dosed the first patient in its Phase 1 clinical trial to evaluate the safety of AB-SA01, AmpliPhi's proprietary phage cocktail targeting Staphylococcus aureus (S. aureus) infections, administered topically to the intact skin of healthy adults. The trial is being conducted under a Collaborative Research and Development Agreement with the U.S. Army and at the Walter Reed Army Institute of Research Clinical Trials Center in Silver Spring, Maryland.
APHB: 2.06 (-0.14)
AmpliPhi Biosciences Reports First Quarter 2016 Financial Results and Provides Corporate Update
BusinessWire - Thu May 12, 3:15PM CDT
AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced its financial results for the first quarter ended March 31, 2016.
APHB: 2.06 (-0.14)
AmpliPhi Biosciences to Host Conference Call and Webcast Discussion of First Quarter 2016 Financial Results on May 13, 2016
BusinessWire - Tue May 10, 7:45AM CDT
AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it will report financial results for the quarter ended March 31, 2016 on Thursday, May 12. AmpliPhi management will host a conference call at 8:30 a.m. Eastern Time on May 13, 2016 to review financial results and provide a corporate update.
APHB: 2.06 (-0.14)
AmpliPhi Biosciences Provides Update on Phase I Trial: Phage Therapy Well Tolerated in First Cohort
BusinessWire - Wed Apr 20, 11:30AM CDT
AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today provided an update on the progress of its ongoing first-in-man Phase I clinical trial for chronic rhinosinusitis patients treated with AmpliPhi's proprietary phage cocktail AB-SA01.
APHB: 2.06 (-0.14)
AmpliPhi Biosciences Terminates Collaboration Agreement with Intrexon
BusinessWire - Thu Apr 14, 7:45AM CDT
AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it has provided written notice to Intrexon to cancel the Exclusive Channel Collaboration (ECC) with Intrexon.
APHB: 2.06 (-0.14)
AmpliPhi Biosciences Presents Data Showing Bacteriophage Product Candidate Kills Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients
BusinessWire - Tue Apr 12, 3:15PM CDT
AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, presented data at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) summarizing both the in vitro and in vivo activity of its proprietary, investigational phage mix AB-PA01.
APHB: 2.06 (-0.14)
AmpliPhi Biosciences Reports Full-Year 2015 Financial Results
BusinessWire - Wed Mar 30, 3:15PM CDT
AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced its financial results for the fiscal year ended December 31, 2015.
XON: 28.96 (-1.03), APHB: 2.06 (-0.14)
AmpliPhi Biosciences to Host Full-Year 2015 Financial Results Conference Call and Webcast on March 30, 2016
BusinessWire - Tue Mar 29, 7:45AM CDT
AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it will report financial results for the fiscal year ended December 31, 2015 on Wednesday, March 30, 2016. AmpliPhi management will host a conference call at 4:30 pm Eastern Time on March 30, 2016 to review financial results and provide a corporate update.
XON: 28.96 (-1.03), APHB: 2.06 (-0.14)
AmpliPhi Biosciences CEO to Present at 28th Annual ROTH Conference
BusinessWire - Tue Mar 08, 7:45AM CST
AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that M. Scott Salka, AmpliPhi's CEO, will present a corporate overview on Tuesday, March 15, 2016 at the 28th Annual ROTH Conference at the Ritz Carlton in Dana Point, California.
XON: 28.96 (-1.03), APHB: 2.06 (-0.14)
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2015 - 78 Companies & Drug Profiles
M2 - Tue Feb 09, 10:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/ctt3q8/methicillinresist) has announced the addition of the "Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infectionsand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Methicillin-Resistant Staphylococcus Aureus (MRSA) InfectionsOverview - Therapeutics Development - Pipeline Products for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Overview - Pipeline Products for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Comparative Analysis - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics under Development by Companies - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics under Investigation by Universities/Institutes - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Products under Development by Companies - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Products under Investigation by Universities/Institutes - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Companies Involved in Therapeutics Development Companies Mentioned - Absynth Biologics Limited - Adenium Biotech ApS - AIMM Therapeutics B.V. - Alchemia Limited - Allergan Plc - AlphaMab Co., Ltd - Alvogen Korea - AmpliPhi Biosciences Corporation - AnGes MG, Inc. - Aphios Corporation - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bharat Biotech International Limited - BioDiem Ltd - BioSource Pharm, Inc. - C3 Jian, Inc - Cellceutix Corporation - Cempra, Inc. - ContraFect Corporation - CrystalGenomics, Inc. - CSA Biotechnologies LLC - Debiopharm International S.A. - DesignMedix, Inc. - Destiny Pharma Limited - Dong-A Socio Group - Ensol Biosciences Inc. - Excelimmune, Inc. - Galapagos NV - GangaGen Inc. - Helix BioMedix, Inc. - Hsiri Therapeutics, LLC - Ildong Pharmaceutical Co., Ltd. - Immupharma Plc - ImmuVen, Inc. - iNtRON Biotechnology Inc. For more information visit http://www.researchandmarkets.com/research/ct...llinresist
AGN: 246.96 (-0.16), AZN: 29.73 (+0.06), CEMP: 18.73 (-1.11), APHB: 2.06 (-0.14), GLPG: 60.01 (+2.51)
AmpliPhi Biosciences Announces Award of Federal Research Grant from Australia to its Collaboration Partner, Westmead Institute
BusinessWire - Tue Feb 09, 7:45AM CST
AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, congratulates the Westmead Institute's Centre for Infectious Diseases and Microbiology for winning an AUD $860,000 grant from the Australian Government to isolate and develop phages that target two serious human pathogens, E. Coli and Klebsiella. AmpliPhi will participate in the project by providing its proprietary expertise in bacteriophage isolation, characterization and manufacturing scale-up.
XON: 28.96 (-1.03), APHB: 2.06 (-0.14)
Acinetobacter Infections Pipeline Review, H2 2015
M2 - Tue Feb 02, 5:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/923dq5/acinetobacter) has announced the addition of the "Acinetobacter Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acinetobacter Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acinetobacter Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Acinetobacter Infections Overview - Therapeutics Development - Pipeline Products for Acinetobacter Infections - Overview - Pipeline Products for Acinetobacter Infections - Comparative Analysis - Acinetobacter Infections - Therapeutics under Development by Companies - Acinetobacter Infections - Therapeutics under Investigation by Universities/Institutes - Acinetobacter Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acinetobacter Infections - Products under Development by Companies - Acinetobacter Infections - Products under Investigation by Universities/Institutes - Acinetobacter Infections - Companies Involved in Therapeutics Development - Achaogen Inc. - Adenium Biotech ApS - AmpliPhi Biosciences Corporation - Aridis Pharmaceuticals LLC - AstraZeneca Plc - AvidBiotics Corp. - Emergent BioSolutions Inc. - Evaxion Biotech - F. Hoffmann-La Roche Ltd. - FAB Pharma - FOB Synthesis, Inc. - LegoChem Biosciences, Inc - Melinta Therapeutics, Inc - Microbiotix, Inc. - MicuRx Pharmaceuticals, Inc. - Nosopharm SAS - Novan, Inc. - Omnia Molecular Ltd. - Pfizer Inc. - Phylogica Limited - Sarepta Therapeutics, Inc. - Sealife PHARMA GMBH - Shionogi & Co., Ltd. - Synthetic Biologics, Inc. - Techulon, Inc. - Tetraphase Pharmaceuticals Inc. - Trana Discovery, Inc. - Vaxdyn, S.L. For more information visit http://www.researchandmarkets.com/research/92...netobacter
TTPH: 4.38 (-0.17), SYN: 2.09 (-0.02), EBS: 43.71 (+0.07), SRPT: 15.57 (-0.14), PFE: 34.69 (-0.18), AZN: 29.73 (+0.06), AKAO: 3.93 (+0.32), APHB: 2.06 (-0.14)
Cystic Fibrosis - Pipeline Review, H2 2015
M2 - Wed Jan 27, 8:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/llcrjt/cystic_fibrosis) has announced the addition of the "Cystic Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cystic Fibrosis. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Actelion Ltd - Akari Therapeutics, Plc - Alaxia SAS - AlgiPharma AS - AmpliPhi Biosciences Corporation - Arcturus Therapeutics, Inc - Aridis Pharmaceuticals LLC - Bayer AG - Boehringer Ingelheim GmbH - Carolus Therapeutics, Inc. - Celtaxsys, Inc. - Chiesi Farmaceutici SpA - Cilian AG - Concert Pharmaceuticals, Inc. - Corbus pharmaceuticals, Inc. - Cyclacel Pharmaceuticals, Inc. - DiscoveryBiomed, Inc. - Errant Gene Therapeutics, LLC - Galapagos NV - GlaxoSmithKline Plc - Grifols, S.A. - Grupo Praxis Pharmaceutical SA - Horizon Pharma Plc - Insmed Incorporated - Invion Limited - JHL Biotech, Inc. - Kamada Ltd. - La Jolla Pharmaceutical Company - Lamellar Biomedical Ltd - Laurent Pharmaceuticals Inc. - (30 Others) For more information visit http://www.researchandmarkets.com/research/ll...c_fibrosis
INSM: 11.93 (-0.42), CYCC: 4.40 (-0.18), HZNP: 17.81 (-0.08), KMDA: 3.71 (-0.04), GSK: 42.89 (+0.48), AKTX: 14.00 (-0.19), APHB: 2.06 (-0.14), CNCE: 13.42 (+0.02), GLPG: 60.01 (+2.51)
Pseudomonas Aeruginosa Infections Therapeutics Pipeline Review, H2 2015
M2 - Fri Jan 22, 5:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/npjzdg/pseudomonas) has announced the addition of the "Pseudomonas Aeruginosa Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pseudomonas Aeruginosa Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pseudomonas Aeruginosa Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pseudomonas Aeruginosa Infections Overview - Therapeutics Development - Pipeline Products for Pseudomonas Aeruginosa Infections - Overview - Pipeline Products for Pseudomonas Aeruginosa Infections - Comparative Analysis - Pseudomonas Aeruginosa Infections - Therapeutics under Development by Companies - Pseudomonas Aeruginosa Infections - Therapeutics under Investigation by Universities/Institutes - Pseudomonas Aeruginosa Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pseudomonas Aeruginosa Infections - Products under Development by Companies - Pseudomonas Aeruginosa Infections - Products under Investigation by Universities/Institutes - Pseudomonas Aeruginosa Infections - Companies Involved in Therapeutics Development - Achaogen Inc. - Adenium Biotech ApS - Aeolus Pharmaceuticals, Inc. - AlgiPharma AS - AmpliPhi Biosciences Corporation - AnGes MG, Inc. - Arch Biopartners, Inc. - Aridis Pharmaceuticals LLC - Arno Therapeutics, Inc. - AstraZeneca Plc - Biolytics Pharma - CSA Biotechnologies LLC - Evaxion Biotech - F. Hoffmann-La Roche Ltd. - FOB Synthesis, Inc. - GlaxoSmithKline Plc - GlycoMimetics, Inc. - Hsiri Therapeutics, LLC - Insmed Incorporated - Lascco SA - LegoChem Biosciences, Inc - Lytix Biopharma AS - MedImmune, LLC - Nosopharm SAS - Novabiotics Limited - Novan, Inc. - Omnia Molecular Ltd. - Pfizer Inc. - Polyphor Ltd. - Sanofi - Sarepta Therapeutics, Inc. - Sealife PHARMA GMBH - Sequoia Sciences, Inc. - Shionogi & Co., Ltd. - Soligenix, Inc. For more information visit http://www.researchandmarkets.com/research/np...seudomonas
INSM: 11.93 (-0.42), PFE: 34.69 (-0.18), AKAO: 3.93 (+0.32), GLYC: 8.97 (+0.29), GSK: 42.89 (+0.48), APHB: 2.06 (-0.14), SRPT: 15.57 (-0.14), ACH: 7.64 (-0.02), AZN: 29.73 (+0.06)
AmpliPhi Biosciences doses CRS patient with AB-SA01 in Phase 1 clinical trial
M2 - Thu Jan 21, 3:51AM CST
Antibacterial company AmpliPhi Biosciences (NYSEMKT:APHB) revealed on Wednesday that it has started treatment of the first patient under its Phase 1 clinical trial of AB-SA01 in Staphylococcus aureus (S. aureus) infections with chronic rhinosinusitis (CRS) that fail to respond to standard antibiotic treatment.
APHB: 2.06 (-0.14)
AmpliPhi Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial of AB-SA01
BusinessWire - Wed Jan 20, 7:45AM CST
AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announces it has dosed the first patient in its Phase 1 clinical trial of AB-SA01 for the treatment of Staphylococcus aureus (S. aureus) infections in patients with chronic rhinosinusitis (CRS) that fail to respond to standard antibiotic treatment.
XON: 28.96 (-1.03), APHB: 2.06 (-0.14)
